Finasteride prolongs time off ADT in intermittent ADT

[JimJimJimJim]

Intermittent Androgen Deprivation (IAD) with Finasteride (F) Given During the Induction and Maintenance Periods Results in Prolonged Time off IAD in Patients with Localized Prostate Cancer (LPC). (Meeting abstract).

Print Print this page

Sub-category:

Genitourinary Cancer

Category:

Genitourinary Cancer

Meeting:

1999 ASCO Annual Meeting

Abstract No: 1363

Author(s):

S Strum, J McDermed, L Madsen, M Scholz

Abstract:

Limited clinical data show modest F activity against PC. We examined patient (pt)- and treatment-related factors in hormone-naive pts electing to discontinue androgen blockade (AB) to determine if F added any measurable benefits. Fifty-nine LPC pts received AB, 32 (54%) with a luteinizing-hormone releasing-hormone agonist (LHRH-A)+an antiandrogen (AA) and 27 (46%) with a LHRH-A, AA+F (10mg/day). F was included in induction and continued as maintenance after IAD was stopped. Pts had to achieve and maintain an undetectable (UD) PSA (<0.05ng/ml) on AB and be assessable off IAD >=12 months (mo). Clinical stage (CS) included PSA relapse after a local treatment (n=25), T1c (n=8) and T2a-c (n=26). PSA endpoints off IAD were defined as PSA increases to 2.5ng/ml and 5.0ng/ml for pts who did and did not receive F, respectively. Factors analyzed were: pt age, baseline testosterone (BT), baseline PSA (bPSA), time to reach UD-PSA (TTUD-PSA), UD time on AB (UDT) and testosterone recovery to >=150ng/ml (T150). Significant differences between groups appear in the table below: Despite similar T150, PSA velocity was significantly blunted in F pts v non-F pts. This yielded a median of 15 additional months off IAD until PSA endpoints were reached. F was well tolerated with 2 50% dose reduction for diminished libido. Only 5 (19%) F-treated pts restarted IAD after a median follow-up of 36 mo (range 17+ -70+ mo). We conclude F during IAD induction and maintenance significantly prolongs time off therapy independent of T150. [jm: IAD3]